Endoscopic anterior fundoplication with the Medigus Ultrasonic Surgical Endostapler (MUSE™) for gastroesophageal reflux disease: 6-month results from a multi-center prospective trial
Authors:
- Johannes ZacherlJZJohannes Zacherl
- Aviel Roy-ShapiraARAviel Roy-Shapira
- Luigi BonavinaLuigi Bonavina
- Amol BapayeABAmol Bapaye
- Sebastian F. SchoppmannSSSebastian F. Schoppmann
- William R. KesslerWKWilliam R. Kessler
- Don J. SelzerDSDon J. Selzer
- Ryan C. BroderickRBRyan C. Broderick
- Glen A. LehmanGLGlen A. Lehman
- Santiago HorganSHSantiago Horgan
Open Access
- 19 August 2014
- journal article
- clinical trial
- Published by Springer Nature in Surgical Endoscopy
- Vol. 29 (1) , 220-229
Abstract
Background Both long-term proton pump inhibitor (PPI) use and surgical fundoplication have potential drawbacks as treatments for chronic gastroesophageal reflux disease (GERD). This multi-center, prospective study evaluated the clinical experiences of 69 patients who received an alternative treatment: endoscopic anterior fundoplication with a video- and ultrasound-guided transoral surgical stapler. Methods Patients with well-categorized GERD were enrolled at six international sites. Efficacy data was compared at baseline and at 6 months post-procedure. The primary endpoint was a ≥50 % improvement in GERD health-related quality of life (HRQL) score. Secondary endpoints were elimination or ≥50 % reduction in dose of PPI medication and reduction of total acid exposure on esophageal pH probe monitoring. A safety evaluation was performed at time 0 and weeks 1, 4, 12, and 6 months. Results 66 patients completed follow-up. Six months after the procedure, the GERD-HRQL score improved by >50 % off PPI in 73 % (48/66) of patients (95 % CI 60–83 %). Forty-two patients (64.6 %) were no longer using daily PPI medication. Of the 23 patients who continued to take PPI following the procedure, 13 (56.5 %) reported a ≥50 % reduction in dose. The mean percent of total time with esophageal pH <4.0 decreased from baseline to 6 months (P < 0.001). Common adverse events were peri-operative chest discomfort and sore throat. Two severe adverse events requiring intervention occurred in the first 24 subjects, no further esophageal injury or leaks were reported in the remaining 48 enrolled subjects. Conclusions The initial 6-month data reported in this study demonstrate safety and efficacy of this endoscopic plication device. Early experience with the device necessitated procedure and device changes to improve safety, with improved results in the later portion of the study. Continued assessment of durability and safety are ongoing in a three-year follow-up study of this patient group.Keywords
This publication has 29 references indexed in Scilit:
- Esophageal Sphincter Device for Gastroesophageal Reflux DiseaseNew England Journal of Medicine, 2013
- The LINX® reflux management system: confirmed safety and efficacy now at 4 yearsSurgical Endoscopy, 2012
- Systematic review: the burden of disruptive gastro‐oesophageal reflux disease on health‐related quality of lifeAlimentary Pharmacology & Therapeutics, 2012
- Proton Pump Inhibitors and Risk of Fractures: A Meta-Analysis of 11 International StudiesThe American Journal of Medicine, 2011
- Preclinical trial of a modified gastroscope that performs a true anterior fundoplication for the endoluminal treatment of gastroesophageal reflux diseaseSurgical Endoscopy, 2009
- Antireflux Transoral Incisionless Fundoplication Using EsophyX: 12‐Month Results of a Prospective Multicenter StudyWorld Journal of Surgery, 2008
- Endoluminal fundoplication by a transoral device for the treatment of GERD: A feasibility studySurgical Endoscopy, 2007
- Proton-Pump Inhibitor Therapy in Patients with Gastro-Oesophageal Reflux DiseaseDrugs, 2007
- Risk factors and the prevalence of trocar site herniation after laparoscopic fundoplicationSurgical Endoscopy, 2001
- The gastroesophageal flap valve: in vitro and in vivo observationsGastrointestinal Endoscopy, 1996